$1.32
0.76%
Nasdaq, Sep 24, 04:00 pm EDT. Closed.
ISIN
US67022C1062
Symbol
NCNA

NuCana plc Sponsored ADR Stock price

$1.32
-0.15 10.20% 1M
-0.27 16.98% 6M
-2.28 63.33% YTD
-2.83 68.19% 1Y
-2,986.18 99.96% 3Y
-11,998.68 99.99% 5Y
-80,748.68 100.00% 10Y
-80,748.68 100.00% 20Y
Nasdaq, Closing price Thu, Sep 24 2026
+0.01 0.76%
ISIN
US67022C1062
Symbol
NCNA
Industry

Is NuCana plc Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
$5.7m
Enterprise Value
$-19.2m
Net debt
positive
Cash
$25.8m
Shares outstanding
21.5b
Valuation (TTM | estimate)
P/E
-
P/S
- | -
EV/Sales
- | -
EV/FCF
2.7
P/B
0.2
Financial Health
Equity Ratio
81.5%
Return on Equity
-120.7%
ROCE
-69.8%
ROIC
-256.5%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-19.0m
EBIT
$-19.3m
Net Income
$-12.8m
Free Cash Flow
$-7.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
29.7%
EBIT
29.7%
Net Income
69.4%
Free Cash Flow
73.2%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
$0.0
FCF per Share
$0.0
Short interest
3.8%
Employees
11
Rev per Employee
$0.0

NuCana plc Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a NuCana plc Sponsored ADR forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a NuCana plc Sponsored ADR forecast:

Buy
75%
Hold
25%

Financial data from NuCana plc Sponsored ADR

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.95 6.95
30% 30%
-
- Research and Development Expense 12 12
30% 30%
-
-19 -19
30% 30%
-
- Depreciation and Amortization 0.37 0.37
27% 27%
-
EBIT (Operating Income) EBIT -19 -19
30% 30%
-
Net Profit -13 -13
69% 69%
-

In millions USD.

Don't miss a Thing! We will send you all news about NuCana plc Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NuCana plc Sponsored ADR Stock News

Neutral
GlobeNewsWire
●
about one month ago
Final Data from Phase 2 Expansion Study of NUC-7738 Remains on Track for 2026 Advancing Additional Indications and Combination Strategies for NUC-7738 Cash Runway Expected to Extend into 2029 EDINBURGH, United Kingdom, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) today announced financial results for the second quarter ended June 30, 2026 and provided ...
Neutral
GlobeNewsWire
●
4 months ago
EDINBURGH, United Kingdom, June 01, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer, announced the appointment of Ian Webster as Chief Financial Officer, effective today. Ian has served as Interim Chief Financial Officer since June 2025 and wa...
Neutral
GlobeNewsWire
●
4 months ago
Final Data from Phase 2 Expansion Study of NUC-7738 Expected in 2026 NUC-7738 Receives FDA IND Clearance: Planned Initial Studies to Focus on Melanoma Advancing Additional Indications and Combination Strategies Cash Runway Expected to Extend into 2029 EDINBURGH, United Kingdom, May 14, 2026 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) today announced financial resul...

Company Profile

NuCana Plc engages in the development of technology platform for the treatment of patients with cancer. Its Protide technology consists of acelarin, NUC-3373 and NUC-7738. The company was founded by Hugh S. Griffith and Christopher B. Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.

Head office United Kingdom
CEO Mr. Griffith
Employees 11
Founded 1997
Website www.nucana.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today